Evidence map›Paper›PMID 40241028›Full record

SynthesisBMC cancer2025

Incidence and risk factors of sarcopenia in gastric cancer patients: a meta-analysis and systematic review.

Mingyue Fu, Xuehong Wang, Jing Zhou, Jianfeng Wang

Abstract readSystematic ReviewMeta-Analysis
In one paragraph

Synthesis in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Simple clinical parameters to identify sarcopenia 1 year after gastrectomy for gastric cancer.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026
    Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mingyue FuQinghai University Affiliated Hospital (School of Clinical Medicine), Qinghai University, Qinghai Xining, 810016, China.
Xuehong WangDepartment of Gastroenterology, Qinghai University Affiliated Hospital, No.29 Tongren Road, Chengxi District, Qinghai Xining, Qinghai Province, 810000, China. lindawang0710@hotmail.com.
Jing ZhouQinghai University Affiliated Hospital (School of Clinical Medicine), Qinghai University, Qinghai Xining, 810016, China.
Jianfeng WangQinghai University Affiliated Hospital (School of Clinical Medicine), Qinghai University, Qinghai Xining, 810016, China.

Funding

Clinical Medical Research Center for Digestive Diseases of Qinghai Province 2019-SF-L3Key Clinical Specialty Construction Project of Qinghai Province 2022-118
6 · The paper itself

Abstract

backgroundThis meta-analysis was to assess the incidence and risk factors of sarcopenia in gastric cancer (GC) patients and to provide clinical implications for the prevention and improvement of sarcopenia in GC patients.

methodsPubMed, Embase, Cochrane, Web of Science, CNKI, Wanfang, and VIP databases (language was limited to Chinese and English) were searched for observational studies. The random-effects model was used to analyze the incidence of GC combined with sarcopenia and the odd ratio (OR) and 95% confidence interval (CI) of risk factors.

results1244 studies were retrieved and 20 eligible studies were included. The meta-analysis revealed that the incidence of sarcopenia in GC patients was 26.6% (95% CI: 21%~32%). Age (OR = 1.128, 95% CI: 1.056 ~ 1.204, P < 0.001), male (OR = 1.054, 95% CI: 0.620 ~ 1.791, P < 0.005), body mass index (OR = 1.117, 95% CI: 0.881 ~ 1.414, P < 0.001), nutritional risk screening 2002 (OR = 3.953, 95% CI: 2.038 ~ 7.668, P < 0.05), and tumor diameter > 3 cm (OR = 1.515, 95% CI: 1.021 ~ 2.248, P < 0.05) may be risk factors for sarcopenia in GC patients. In contrast, tumor stage (OR = 1.907, 95% CI: 0.967 ~ 3.763, P > 0.05), gastrectomy approach (OR = 1.837, 95% CI: 1.237 ~ 2.727, P > 0.05), differentiation type (OR = 0.586, 95%CI: 0.325 ~ 1.059, P > 0.05), and severe adverse reactions (NLR, HB, ALB) after chemotherapy (OR = 0.926, 95%CI: 0.793 ~ 1.082, P > 0.05) had no significant correlation with sarcopenia in GC patients.

conclusionsThis meta-analysis shows an increased prevalence of sarcopenia in GC patients. This analysis, which focused on Asian populations, suggested that high nutritional risk was a risk factor for sarcopenia in GC patients. Age over 65 years and tumor diameter over 3 cm may be risk factors for sarcopenia. Men may be prone to sarcopenia. Targeting these risk factors may be beneficial in the prevention of sarcopenia in GC patients.

Indexed as

SarcopeniaStomach NeoplasmsBody Mass IndexFemaleHumansIncidenceMaleRisk FactorsGastric cancerIncidenceRisk factorsSarcopenia

Identifiers

PMID40241028
PMCPMC12004572

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.